Alicia Uijl presents the results of an analysis that identified five phenotypic clusters in HFpEF with differences in medication profile, morbidity and mortality.

Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.

This study showed that prescription rates of evidence-based medical therapies are suboptimal in patients with comorbid HFrEF and CKD, even at eGFR levels where therapies are not contraindicated by kidney dysfunction.

This analysis of the PIVOTAL trial showed that treatment with high-dose IV iron administered proactively, compared to low-dose IV iron administered reactively, decreased the occurrence of first and recurrent HF events in patients receiving hemodialysis.

EMPEROR-Preserved met its primary endpoint and showed a significant risk reduction with empagliflozin for the composite endpoint of time to first event of CV death or HF hospitalization compared to placebo in adults with HFpEF, with or without T2DM.

ESC HF 2021 Dapagliflozin improved HF symptoms (measured by KCCQ-TSS) in HFrEF compared to placebo, but did not improve physical limitations (measured by KCCQ-PLS) or 6 minute walk distance. No significant improvements with dapagliflozin in any of these outcomes were seen in HFpEF.

ESC HF 2021 This analysis of the VICTORIA trial showed that the beneficial effects of vericiguat were unaffected by AF status at baseline.

ESC HF 2021 This post hoc analysis of the TRANSITION study demonstrated that early initiation and up-titration of sacubitril/valsartan after acute decompensated HF was well tolerated in HFrEF patients with CKD.

ESC HF 2021 The IRON-CRT trial showed that ferric carboxymaltose improved cardiac function as measured by LVEF, LVESV, and the force-frequency relationship in patients with HFrEF and iron deficiency.

ESC HF 2021 A subanalysis of FIDELIO-DKD showed that finerenone lowered CV and kidney outcomes compared to placebo in patients with T2DM and CKD irrespective of pre-existing HF status.

ESC HF 2021 In a nation-wide HF registry, screening for iron deficiency was performed in only 27% of patients. 19% Of patients with iron deficiency received treatment with ferric carboxymaltose.

ESC HF 2021 Key messages of the 2021 ESC/HFA Guidelines for Heart Failure include a simplified treatment algorithm for HFrEF based on early administration of 4 classes of drugs, including SGLT2i, and tailored-treatment approaches based on phenotypes.